Agreement - August 4, 2017
BioInvent and ThromboGenics amend agreement
BioInvent International and ThromboGenics NV announce that they have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317. The revisions to the existing agreement have been aligned with each company’s strategic ambitions and therapeutic focus. The novel anti-PIGF monoclonal antibody is currently being developed […]
Clinical Trials - January 12, 2017
ThromboGenics initiates Phase II study
BioInvent’s collaboration partner ThromboGenics initiates Phase II study with the drug candidate THR-317. BioInvent International AB announces today that the company’s collaboration partner ThromboGenics NV reports that the first patients have been enrolled in a study with the drug candidate THR-317 for the treatment of diabetic macular oedema. The study evaluates safety and efficacy of […]
Agreement - December 21, 2016
BioInvent announce collaboration and license agreement with Pfizer
BioInvent International has entered into a cancer immunotherapy research collaboration and license agreement with Pfizer to develop antibodies targeting tumour-associated myeloid cells. Under the terms of the deal, Pfizer will pay BioInvent approximately $10 million in early payments, including an upfront payment, early research funding, and a $6 million equity investment in new shares of […]
Clinical Trials - December 12, 2016
BioInvent terminates Phase II study
BioInvent International announces that it has decided to terminate its current clinical Phase II study with BI-505 in multiple myeloma. The decision follows BioInvent’s review and discussion with the US Food & Drug Administration (FDA), who put BI-505 on full clinical hold in November 2016. The terminated trial, which was performed in collaboration with Penn […]
Clinical Trials - November 9, 2016
BioInvent reports clinical hold on BI-505 phase II study
BioInvent International has received verbal notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold (i.e. no further dosing of patients) has been placed on BioInvent’s current clinical Phase II study with the antibody BI-505 in patients with multiple myeloma. BioInvent has not yet received written notice of the clinical hold […]
Intellectual Property - September 24, 2016
BioInvent expands patent approvals
BioInvent International announces that it has been granted additional patent protection in Japan, Russia and China for BI-505, its lead immune-oncology programme currently in Phase II for the treatment of multiple myeloma. These patents cover the use of BI-505 in the treatment of patients previously treated for cancer that have either not responded or subsequently […]
